Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Intervention(s):

  • Drug: Neratinib
  • Drug: Fulvestrant
  • Drug: Trastuzumab
  • Procedure: Tumor biopsy
  • Procedure: Research blood sample

Phase:

Phase 2

Eligibility


Inclusion Criteria for Pre-registration (for patients with unknown HER2 mutation status to
have tumor tissue screened centrally by Washington University GPS laboratory):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Agree to provide archival tumor material for research

   - There is no limitation on the number of prior lines of systemic therapy.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status ≤ 2

   - Adequate organ function as defined below within 8 weeks of pre-registration:

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 × ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

Note: HER2 mutation testing may be performed while the patient is receiving active systemic
therapy for metastatic breast cancer so that the result can be used to determine
eligibility for study drug therapy in the future.

Exclusion Criteria for Pre-registration:

   - Testing for LVEF is not required for pre-registration, but patient must not have a
   recent LVEF < LLN or have symptoms of congestive heart failure.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
   situations that would limit compliance with study requirements.

   - Acute or currently active hepatic or biliary disease requiring antiviral therapy (with
   the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases, or
   stable chronic liver disease per investigator assessment).

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

Inclusion Criteria for Registration (for patients initially pre-registered and with HER2
mutation identified by Washington University GPS laboratory)

   - Tumor tissue tested positive for HER2 mutation. HER2 mutations detected by Guardant360
   are also eligible.

   - Agree to provide archival tumor material for research

   - ECOG performance status ≤2

   - Adequate organ function as defined below within 2 weeks of registration:

      - ANC ≥1.5 x 10^9/L

      - Platelet count ≥100 x 10^9/L

      - Serum creatinine ≤1.5 x ULN

      - Total bilirubin ≤1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is
      allowed)

      - AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic chemotherapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known brain metastasis are eligible, but must have received radiation
   and be off steroids and stable (without evidence of disease progression by imaging or
   exam) for 3 months.

   - QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > or = institutional ILLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product.

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naive ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology form an earlier
   time point could be used and a discussion with the study chair is required.

Inclusion Criteria for Registration (for patients with HER2 mutation identified at an
outside CLIA certified location):

   - Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
   non-amplified by FISH) breast cancer that is stage IV.

   - Tumor tissue or circulating tumor DNA tested positive for HER2 mutation. Mutations
   outside the list will be assessed on a case-by-case basis by the study team to
   determine eligibility.

   - Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except
   to be eligible for the Part II fulvestrant-naïve ER+ cohort, at least one measurable
   disease by RECIST 1.1 is required.

   - At least 18 years of age.

   - ECOG performance status < 2 (see Appendix A).

   - Adequate organ function as defined below within 2 weeks of registration:

      - Absolute neutrophil count: ≥1.5 × 109/L (1500/mm3)

      - Platelet count: ≥100 × 109/L (100,000/mm3)

      - Serum creatinine: ≤1.5 x ULN

      - Total bilirubin: ≤1.5 × ULN (in case of known Gilbert's syndrome, <2 x ULN is
      allowed)

      - AST and ALT: ≤3× ULN or ≤ 5 x ULN for patients with liver metastases.

   - The patient must have completed radiation therapy and be at least 1 week from the last
   systemic therapy administration, with adequate recovery of bone marrow and organ
   functions, before starting neratinib.

   - Presence of disease progression on the most recent disease evaluation.

   - Patients with known treated brain metastasis are eligible, but must have received
   radiation and be off steroids and stable (without evidence of disease progression by
   imaging or exam) for 3 months.

   - QTc interval ≤ 450 msec for men or ≤ 470 msec for women within 2 weeks of
   registration.

   - LVEF > institutional LLN within 4 weeks of registration.

   - Women of childbearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control, abstinence) prior to study entry and for
   the duration of study participation. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she must inform her treating physician
   immediately. Men must agree and commit to use a barrier method of contraception while
   on treatment and for 3 months after the last dose of the investigational product

   - Able to understand and willing to sign an IRB approved written informed consent
   document.

   - There is no limitation on the number of prior lines of systemic therapy.

   - To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with
   fulvestrant is not allowed. In addition, ER and/or PR positivity by institutional
   standard is required on pathology from the most recent tumor specimen if biopsy was
   done unless the tissue source (for example, pleural effusion or ascites or bone
   biopsy) may yield false negative ER and/or PR result, in which case the pathology from
   an earlier time point could be used and a discussion with the study chair is required.

   - To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease
   progression on fulvestrant is required. In addition, ER and/or PR positivity by
   institutional standard is required on pathology from the most recent tumor specimen
   unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may
   yield false negative ER and/or PR result, in which case the pathology from an earlier
   time point could be used and a discussion with the study chair is required.

Exclusion Criteria for Registration:

   - Currently receiving any other investigational agents or systemic cancer therapy.

   - Currently taking medications and herbal or dietary supplements that are strong
   cytochrome P450 (CYP) 3A4 inducers or inhibitors. The washout period must have been
   completed prior to the start of neratinib if the patient was taking any of these
   agents. If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements.

   - Acute or currently active/requiring antiviral therapy hepatic or biliary disease (with
   the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
   metastases, or stable chronic liver disease per investigator assessment).

   - Pregnant and/or breastfeeding.

   - History of significant cardiac disease, cardiac risk factors, or uncontrolled
   arrhythmias.

   - Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
   resulting in dyspnea at rest.

   - Experiencing grade 2 or greater diarrhea.

   - Prior treatment with neratinib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting